Clinical and laboratory diagnostics of cardiovascular disease: Focus on natriuretic peptides and cardiac ischemia

Scandinavian Journal of Clinical and Laboratory Investigation, Supplement

Volumn 65, Issue 240, 2005, Pages 18-24

  Omland, Torbjørn ^a,b  

^a UNIVERSITY OF OSLO   (Norway)

^b AKERSHUS UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOCHEMICAL MARKER; BRAIN NATRIURETIC PEPTIDE; DOBUTAMINE; UNCLASSIFIED DRUG; AMINO TERMINAL PROBRAIN NATRIURETIC PEPTIDE; NATRIURETIC FACTOR;

BLOOD LEVEL; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; CONFERENCE PAPER; DISEASE MARKER; ELECTROCARDIOGRAM; EXERCISE; HEART FAILURE; HEART INFARCTION; HEART MUSCLE INJURY; HEART MUSCLE ISCHEMIA; HEART MUSCLE PERFUSION; HOSPITAL ADMISSION; HUMAN; ISCHEMIC HEART DISEASE; LABORATORY DIAGNOSIS; MORTALITY; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RECURRENCE RISK; STRESS ECHOCARDIOGRAPHY; THORAX PAIN; ACUTE CORONARY SYNDROME; ACUTE DISEASE; CORONARY ARTERY DISEASE; MEASUREMENT; RISK ASSESSMENT; STRESS; BLOOD; ELECTROCARDIOGRAPHY; REVIEW;

CARDIOVASCULAR DISEASES; CHEST PAIN; CORONARY DISEASE; ELECTROCARDIOGRAPHY; HUMANS; MYOCARDIAL ISCHEMIA; NATRIURETIC PEPTIDE, BRAIN;

EID: 23744474805     PISSN: 0085591X     EISSN: None     Source Type: Journal    
DOI: 10.1080/00365510500236077     Document Type: Conference Paper

References (40)

1. Gibler WB. Evaluation of chest pain in the emergency department. Ann Intern Med 1995;123(4):315-8.
2. Storrow AB, Gibler WB. Chest pain centers: diagnosis of acute coronary syndromes. Ann Emerg Med 2000;35(5):449-61.
3. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation 1995;92(3):657-71.
4. Cannon CP, Hand MH, Bahr R, Boden WE, Christenson R, Gibler WB, et al. Critical pathways for management of patients with acute coronary syndromes: an assessment by the National Heart Attack Alert Program. Am Heart J 2002;143(5):777-89.
5. Cannon CP. Treatment algorithms and critical pathways for acute coronary syndromes. Semin Vasc Med 2003;3(4):425-32.
6. Sudoh T, Kangawa K, Minamino N, Matsuo H. A new natriuretic peptide in porcine brain. Nature 1988;332(6159):78-81.
7. de Lemos JA, McGuire DK, Drazner MH. B-type natriuretic peptide in cardiovascular disease. Lancet 2003 26;362(9380):316-22.
8. Mukoyama M, Nakao K, Hosoda K, Suga S, Saito Y, Ogawa Y, et al. Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest 1991;87(4):1402-12.
9. Ruskoaho H. Cardiac hormones as diagnostic tools in heart failure. Endocr Rev 2003;24(3):341-56.
10. Kinnunen P, Vuolteenaho O, Ruskoaho H. Mechanisms of atrial and brain natriuretic peptide release from rat ventricular myocardium: effect of stretching. Endocrinology 1993;132(5):1961-70.
11. Yandle TG, Richards AM, Gilbert A, Fisher S, Holmes S, Espiner EA. Assay of brain natriuretic peptide (BNP) in human plasma: evidence for high molecular weight BNP as a major plasma component in heart failure. J Clin Endocrinol Metab 1993;76(4):832-8.
12. Yamamoto K, Burnett JC, Jr., Jougasaki M, Nishimura RA, Bailey KR, Saito Y, et al. Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy. Hypertension 1996;28(6):988-94.
13. Omland T, Aakvaag A, Bonarjee VV, Caidahl K, Lie RT, Nilsen DW, et al. Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction. Comparison with plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide. Circulation 1996;93(11):1963-9.
14. Omland T, de Lemos JA, Morrow DA, Antman EM, Cannon CP, Hall C, et al. Prognostic value of N-terminal pro-atrial and pro-brain natriuretic peptide in patients with acute coronary syndromes. Am J Cardiol 2002;89(4):463-5.
15. de Lemos JA, Morrow DA, Bentley JH, Omland T, Sabatine MS, McCabe CH, et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 2001;345(14):1014-21.
16. Kikuta K, Yasue H, Yoshimura M, Morita E, Sumida H, Kato H, et al. Increased plasma levels of B-type natriuretic peptide in patients with unstable angina. Am Heart J 1996;132(1 Pt 1):101-7.
17. Talwar S, Squire IB, Downie PF, Davies JE, Ng LL. Plasma N terminal pro-brain natriuretic peptide and cardiotrophin 1 are raised in unstable angina. Heart 2000;84(4):421-4.
18. Omland T, Aakvaag A, Vik-Mo H. Plasma cardiac natriuretic peptide determination as a screening test for the detection of patients with mild left ventricular impairment. Heart 1996;76(3):232-7.
19. Gerber IL, Stewart RA, Legget ME, West TM, French RL, Sutton TM, et al. Increased plasma natriuretic peptide levels reflect symptom onset in aortic stenosis. Circulation 2003;107(14):1884-90.
20. Sutton TM, Stewart RA, Gerber IL, West TM, Richards AM, Yandle TG, et al. Plasma natriuretic peptide levels increase with symptoms and severity of mitral regurgitation. J Am Coll Cardiol 2003;41(12):2280-7.
21. Kama N, Itoh H, Shirakami G, Nakagawa O, Suga S, Ogawa Y, et al. Rapid ventricular induction of brain natriuretic peptide gene expression in experimental acute myocardial infarction. Circulation 1995 Sep 15;92(6):1558-64.
22. Jougasaki M, Yasue H, Mukoyama M, Nakao K, Takahashi K. Appearance of atrial natriuretic peptide in the ventricles in patients with myocardial infarction. Am Heart J 1990;119(1):92-6.
23. Morita E, Yasue H, Yoshimura M, Ogawa H, Jougasaki M, Matsumura T, et al. Increased plasma levels of brain natriuretic peptide in patients with acute myocardial infarction. Circulation 1993;88(1):82-91.
24. Richards AM, Nicholls MG, Yandle TG, Frampton C, Espiner EA, Turner JG, et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. Circulation 1998;97(19):1921-9.
25. Omland T, Persson A, Ng L, O'Brien R, Karlsson T, Herlitz J, et al. N-terminal pro-B-type natriuretic peptide and long-term mortality in acute coronary syndromes. Circulation 2002;106(23):2913-8.
26. Richards AM, Nicholls MG, Espiner EA, Lainchbury JG, Troughton RW, Elliott J, et al. B-type natriuretic peptides and ejection fraction for prognosis after myocardial infarction. Circulation 2003;107(22):2786-92.
27. James SK, Lindahl B, Siegbahn A, Stridsberg M, Venge P, Armstrong P, et al. N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a Global Utilization of Strategies To Open occluded arteries (GUSTO)-IV substudy. Circulation 2003;108(3):275-81.
28. Heeschen C, Hamm CW, Mitrovic V, Lantelme NH, White HD. N-terminal pro-B-type natriuretic peptide levels for dynamic risk stratification of patients with acute coronary syndromes. Circulation 2004;110(20):3206-12.
29. Kyriakides ZS, Markianos M, Michalis L, Antoniadis A, Nikolaou NI, Kremastinos DT. Brain natriuretic peptide increases acutely and much more prominently than atrial natriuretic peptide during coronary angioplasty. Clin Cardiol 2000;23(4):285-8.
30. Tateishi J, Masutani M, Ohyanagi M, Iwasaki T. Transient increase in plasma brain (B-type) natriuretic peptide after percutaneous transluminal coronary angioplasty. Clin Cardiol 2000;23(10):776-80.
31. Marumoto K, Hamada M, Hiwada K. Increased secretion of atrial and brain natriuretic peptides during acute myocardial ischaemia induced by dynamic exercise in patients with angina pectoris. Clin Sci (Lond) 1995;88(5):551-6.
32. Goetze JP, Christoffersen C, Perko M, Arendrup H, Rehfeld JF, Kastrup J, et al. Increased cardiac BNP expression associated with myocardial ischemia. FASEB J 2003 Jun;17(9):1105-7.
33. Bibbins-Domingo K, Ansari M, Schiller NB, Massie B, Whooley MA. B-type natriuretic peptide and ischemia in patients with stable coronary disease: data from the Heart and Soul study. Circulation 2003;108(24):2987-92.
34. Sabatine MS, Morrow DA, de Lemos JA, Omland T, Desai MY, Tanasijevic M, et al. Acute changes in circulating natriuretic peptide levels in relation to myocardial ischemia. J Am Coll Cardiol 2004;44(10):1988-95.
35. Omland T, Richards AM, Wergeland R, Vik-Mo H. B-type natriuretic peptide and long-term survival in patients with stable coronary artery disease. Am J Cardiol 2005;95(1):24-8.
36. Kragelund C, Gronning B, Kober L, Hildebrandt P, Steffensen R. N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. N Engl J Med 2005;352(7):666-75.
37. Toth M, Vuorinen KH, Vuolteenaho O, Hassinen IE, Uusimaa PA, Leppaluoto J, et al. Hypoxia stimulates release of ANP and BNP from perfused rat ventricular myocardium. Am J Physiol 1994;266(4 Pt 2):H1572-H1580.
38. D'Souza SP, Yellon DM, Martin C, Schulz R, Heusch G, Onody A, et al. B-type natriuretic peptide limits infarct size in rat isolated hearts via KATP channel opening. Am J Physiol Heart Circ Physiol 2003;284(5):H1592-H1600.
39. Ruck A, Gustafsson T, Norrbom J, Nowak J, Kallner G, Soderberg M, et al. ANP and BNP but not VEGF are regionally overexpressed in ischemic human myocardium. Biochem Biophys Res Commun 2004;322(1):287-91.
40. D'Souza SP, Baxter GF. B Type natriuretic peptide: a good omen in myocardial ischaemia? Heart 2003;89(7):707-9